Recent advances in pharmacotherapy—particularly with glucagon‐like peptide‐1 receptor (GLP‐1R) agonists (e.g., semaglutide) and GLP‐1/glucose‐dependent insulinotropic polypeptide (GIP) dual agonists (e.g., tirzepatide)—have significantly reshaped obesity management. Here, GLP1R is linked to obesity disorder.